Pre-made Naptumomab benchmark antibody ( Fab Fusion, anti-TPBG therapeutic antibody, Anti-5T4/M6P1/5T4AG/WAIF1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Naptumomab biosimilar, Fab Fusion, Anti-TPBG Antibody: Anti-5T4/M6P1/5T4AG/WAIF1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-363-1mg	1mg	Inquiry
GMP-Bios-ab-363-10mg	10mg	Inquiry
GMP-Bios-ab-363-100mg	100mg	Inquiry
GMP-Bios-ab-363-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Naptumomab biosimilar, Fab Fusion, Anti-TPBG Antibody: Anti-5T4/M6P1/5T4AG/WAIF1 therapeutic antibody
INN Name	Naptumomab
Target	TPBG
Format	Fab Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2006
Year Recommended	2007
Companies	Active Biotech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Non-small cell lung cancer;Pancreatic cancer;Renal cancer
Development Tech	na